RU2012117896A - Способы и композиции для лечения фиброза глаз - Google Patents
Способы и композиции для лечения фиброза глаз Download PDFInfo
- Publication number
- RU2012117896A RU2012117896A RU2012117896/15A RU2012117896A RU2012117896A RU 2012117896 A RU2012117896 A RU 2012117896A RU 2012117896/15 A RU2012117896/15 A RU 2012117896/15A RU 2012117896 A RU2012117896 A RU 2012117896A RU 2012117896 A RU2012117896 A RU 2012117896A
- Authority
- RU
- Russia
- Prior art keywords
- eye
- lox
- polynucleotide
- loxl2
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Способ лечения фиброза глаз в организме, включающий ингибирование активности белка лизилоксидазы (LOX) или лизилоксидазоподобного белка 2 (LOXL2) в одной или нескольких клетках организма.2. Способ по п.1, в котором ингибируют активность белка лизилоксидазы (LOX).3. Способ по п.2, в котором ингибируют активность лизилоксидазоподобного-белка 2 (LOXL2).4. Способ по п.2, в котором активность LOX ингибируют путем введения антитела против LOX в организм.5. Способ по п.3, в котором активность LOXL2 ингибируют путем введения антитела против LOXL2 в организм.6. Способ по п.1, в котором фиброз глаза возникает в организме, подвергнутом лечению от глаукомы.7. Способ по п.6, в котором лечение глаукомы представляет собой хирургическое вмешательство на глазах.8. Способ по п.7, в котором хирургическое вмешательство представляет собой трабекулэктомию.9. Способ по любому из п.п.1, 3, 6, 7 и 8, в котором антитело против LOX вводят в глаз организма.10. Способ по любому из п.п.1, 2, 6-8, в котором антитело против LOXL2 вводят в глаз организма.11. Способ по любому из п.п.1, 3, 6, 7 и 8, в котором в организм вводят полинуклеотид, кодирующий антитело против LOX.12. Способ по любому из п.п.1, 2 и 6-8, в котором в организм вводят полинуклеотид, кодирующий антитело против LOXL2.13. Способ по п.11, в котором полинуклеотид вводят в глаз организма.14. Способ по п.12, в котором полинуклеотид вводят в глаз организма.15. Способ по п.11, в котором полинуклеотид заключают в вирусный вектор, который выбирают из группы, состоящей из аденоассоциированного вируа (AAV), аденовируса и лентивируса.16. Способ по п.12, в котором полинуклеотид заключают в вирусный вектор, который выбирают из группы, состоящей из аденоассоциированного ви
Claims (22)
1. Способ лечения фиброза глаз в организме, включающий ингибирование активности белка лизилоксидазы (LOX) или лизилоксидазоподобного белка 2 (LOXL2) в одной или нескольких клетках организма.
2. Способ по п.1, в котором ингибируют активность белка лизилоксидазы (LOX).
3. Способ по п.2, в котором ингибируют активность лизилоксидазоподобного-белка 2 (LOXL2).
4. Способ по п.2, в котором активность LOX ингибируют путем введения антитела против LOX в организм.
5. Способ по п.3, в котором активность LOXL2 ингибируют путем введения антитела против LOXL2 в организм.
6. Способ по п.1, в котором фиброз глаза возникает в организме, подвергнутом лечению от глаукомы.
7. Способ по п.6, в котором лечение глаукомы представляет собой хирургическое вмешательство на глазах.
8. Способ по п.7, в котором хирургическое вмешательство представляет собой трабекулэктомию.
9. Способ по любому из п.п.1, 3, 6, 7 и 8, в котором антитело против LOX вводят в глаз организма.
10. Способ по любому из п.п.1, 2, 6-8, в котором антитело против LOXL2 вводят в глаз организма.
11. Способ по любому из п.п.1, 3, 6, 7 и 8, в котором в организм вводят полинуклеотид, кодирующий антитело против LOX.
12. Способ по любому из п.п.1, 2 и 6-8, в котором в организм вводят полинуклеотид, кодирующий антитело против LOXL2.
13. Способ по п.11, в котором полинуклеотид вводят в глаз организма.
14. Способ по п.12, в котором полинуклеотид вводят в глаз организма.
15. Способ по п.11, в котором полинуклеотид заключают в вирусный вектор, который выбирают из группы, состоящей из аденоассоциированного вируа (AAV), аденовируса и лентивируса.
16. Способ по п.12, в котором полинуклеотид заключают в вирусный вектор, который выбирают из группы, состоящей из аденоассоциированного вируа (AAV), аденовируса и лентивируса.
17. Способ по п.15, в котором полинуклеотид заключают в вирусный вектор, который выбирают из группы, состоящей из аденоассоциированного вируа (AAV), аденовируса и лентивируса.
18. Способ по п.16, в котором вирусный вектор представляет собой аденоассоциированный вирус (AAV).
19. Способ по 17, в котором вирусный вектор представляет собой AAV типа 2 или AAV типа 4.
20. Способ по п.18, в котором вирусный вектор представляет собой AAV типа 2 или AAV типа 4.
21. Способ по п.1, в котором организм представляет собой млекопитающее.
22. Способ по п.21, в котором млекопитающее представляет собой человека.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27791809P | 2009-09-29 | 2009-09-29 | |
| US61/277,918 | 2009-09-29 | ||
| US39745610P | 2010-06-11 | 2010-06-11 | |
| US61/397,456 | 2010-06-11 | ||
| PCT/US2010/050542 WO2011041309A1 (en) | 2009-09-29 | 2010-09-28 | Methods and compositions for treatment of ocular fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012117896A true RU2012117896A (ru) | 2013-11-10 |
Family
ID=43780639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012117896/15A RU2012117896A (ru) | 2009-09-29 | 2010-09-28 | Способы и композиции для лечения фиброза глаз |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110076285A1 (ru) |
| EP (1) | EP2482814A4 (ru) |
| JP (1) | JP2013506005A (ru) |
| KR (1) | KR20120091146A (ru) |
| CN (1) | CN102711753A (ru) |
| AU (1) | AU2010300813A1 (ru) |
| BR (1) | BR112012007114A2 (ru) |
| CA (1) | CA2775877A1 (ru) |
| MX (1) | MX2012003759A (ru) |
| RU (1) | RU2012117896A (ru) |
| WO (1) | WO2011041309A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| CA2693310C (en) * | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| US20100203062A1 (en) * | 2009-02-06 | 2010-08-12 | Ingeborg Stalmans | Methods and Compositions for Treatment of Neovascularization |
| EP2467396A4 (en) * | 2009-08-21 | 2012-12-26 | Gilead Biologics Inc | CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2 |
| CN102711821A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗方法和组合物 |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| AU2010283997B2 (en) * | 2009-08-21 | 2015-04-09 | Gilead Biologics, Inc. | Methods and compositions for treatment of pulmonary fibrotic disorders |
| US8680246B2 (en) * | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| US11065275B2 (en) * | 2016-03-08 | 2021-07-20 | University Of Utah Research Foundation | Cross-linking agents and associated methods |
| CN109843306A (zh) | 2016-08-19 | 2019-06-04 | 卡琳缪恩股份有限公司 | 使用自身互补型重组腺相关病毒治疗病症的方法和组合物 |
| EP3503928A4 (en) * | 2016-08-19 | 2020-03-18 | Colorado State University Research Foundation | METHOD AND COMPOSITIONS FOR TREATING DISEASES IN THE HORSE WITH A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS |
| KR20250121159A (ko) | 2016-12-07 | 2025-08-11 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
| WO2019178329A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of Michigan | Compositions and methods for treating graves disease |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| KR20200030875A (ko) | 2018-09-13 | 2020-03-23 | 전남대학교산학협력단 | 트리코스타틴 a를 유효성분으로 포함하는 결막 섬유화 억제용 약학적 조성물 |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
| GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300092B1 (en) * | 1999-01-27 | 2001-10-09 | Millennium Pharmaceuticals Inc. | Methods of use of a novel lysyl oxidase-related protein |
| US20030152926A1 (en) * | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20060134172A1 (en) * | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| IL184627A0 (en) * | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| CA2693310C (en) * | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| US8815946B2 (en) * | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
| WO2010080769A2 (en) * | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| US20100203062A1 (en) * | 2009-02-06 | 2010-08-12 | Ingeborg Stalmans | Methods and Compositions for Treatment of Neovascularization |
| CN102711821A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗方法和组合物 |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| AU2010283997B2 (en) * | 2009-08-21 | 2015-04-09 | Gilead Biologics, Inc. | Methods and compositions for treatment of pulmonary fibrotic disorders |
| EP2467396A4 (en) * | 2009-08-21 | 2012-12-26 | Gilead Biologics Inc | CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2 |
-
2010
- 2010-09-28 JP JP2012532238A patent/JP2013506005A/ja not_active Withdrawn
- 2010-09-28 AU AU2010300813A patent/AU2010300813A1/en not_active Abandoned
- 2010-09-28 CA CA2775877A patent/CA2775877A1/en not_active Abandoned
- 2010-09-28 KR KR1020127010920A patent/KR20120091146A/ko not_active Withdrawn
- 2010-09-28 RU RU2012117896/15A patent/RU2012117896A/ru not_active Application Discontinuation
- 2010-09-28 WO PCT/US2010/050542 patent/WO2011041309A1/en not_active Ceased
- 2010-09-28 US US12/892,574 patent/US20110076285A1/en not_active Abandoned
- 2010-09-28 MX MX2012003759A patent/MX2012003759A/es not_active Application Discontinuation
- 2010-09-28 BR BR112012007114A patent/BR112012007114A2/pt not_active IP Right Cessation
- 2010-09-28 CN CN2010800538989A patent/CN102711753A/zh active Pending
- 2010-09-28 EP EP10821110A patent/EP2482814A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011041309A1 (en) | 2011-04-07 |
| BR112012007114A2 (pt) | 2016-07-05 |
| CN102711753A (zh) | 2012-10-03 |
| MX2012003759A (es) | 2012-07-23 |
| US20110076285A1 (en) | 2011-03-31 |
| JP2013506005A (ja) | 2013-02-21 |
| AU2010300813A1 (en) | 2012-04-26 |
| KR20120091146A (ko) | 2012-08-17 |
| CA2775877A1 (en) | 2011-04-07 |
| EP2482814A4 (en) | 2013-04-03 |
| EP2482814A1 (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012117896A (ru) | Способы и композиции для лечения фиброза глаз | |
| Giamanco et al. | Deconstructing the perineuronal net: cellular contributions and molecular composition of the neuronal extracellular matrix | |
| Cheng et al. | Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections | |
| Ryu et al. | Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma | |
| Lee et al. | Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis | |
| EA202091105A1 (ru) | Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1) | |
| Ridet et al. | Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease | |
| Miyoshi et al. | Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide‐induced stimulation of rat microglial cells by suppressing nuclear factor κB and activator protein‐1 activation | |
| Saavedra et al. | Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron–glia crosstalk | |
| Kim et al. | Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy | |
| NO20075815L (no) | Formuleringer og metoder for behandling av amyloidose | |
| Wang et al. | Echinococcus granulosus sensu stricto: silencing of thioredoxin peroxidase impairs the differentiation of protoscoleces into metacestodes | |
| Muroya et al. | Differences in mRNA expression of calpains, calpastatin isoforms and calpain/calpastatin ratios among bovine skeletal muscles | |
| Wetterau et al. | Topical prolyl hydroxylase domain‐2 silencing improves diabetic murine wound closure | |
| Mourya et al. | Establishment of cell line from embryonic tissue of Pipistrellus ceylonicus bat species from India & its susceptibility to different viruses | |
| Grabowski et al. | The use of ex vivo organ cultures in tick-borne virus research | |
| KR20220030271A (ko) | 헌팅턴병을 치료하기 위한 방법 및 재료 | |
| Anandanarayanan et al. | RNA interference in Fasciola gigantica: Establishing and optimization of experimental RNAi in the newly excysted juveniles of the fluke | |
| Ji et al. | Decellularized matrix of adipose-derived mesenchymal stromal cells enhanced retinal progenitor cell proliferation via the Akt/Erk pathway and neuronal differentiation | |
| Tang et al. | Classic swine fever virus NS2 protein leads to the induction of cell cycle arrest at S-phase and endoplasmic reticulum stress | |
| Sonwane et al. | Inhibition of rabies virus multiplication by siRNA delivered through adenoviral vector in vitro in BHK-21 cells and in vivo in mice | |
| KR20140101025A (ko) | 상온에서의 세포 보호와 생존력 향상을 위한 과산화수소가 포함된 산소 방출 미세캡슐 조성물 | |
| Fang et al. | Bone marrow stromal cells attenuate oxygen and glucose deprivation followed by re‑oxygenation‑induced brain microvascular endothelial cell injury | |
| WO2021232165A1 (en) | Recoded oncolytic viruses for treatment of cancer | |
| ATE449165T1 (de) | Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20130930 |